文献速递肿瘤 PET/CT

使用[18F]FDG PET/CT识别原发灶不明肿瘤患者的原发肿瘤:系统综述与个体患者数据Meta分析

Identifying the primary tumour in patients with cancer of unknown primary (CUP) using [18F]FDG PET/CT: a systematic review and individual patient data meta-analysis.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2024-08-14

该系统综述与个体患者数据Meta分析纳入2005年1月至2024年2月文献,共32项研究1865例原发灶不明肿瘤(CUP)患者,按主要转移部位分组比较[18F]FDG PET/CT检出原发肿瘤的诊断效能。汇总检出率从脑转移为主组的0.74至软组织转移为主组的0.35不等,提示检出能力取决于转移部位分布,需针对不同人群制定更个体化的诊断策略并探索新型PET示踪剂或全身(PET/)MRI。

要点

  • 共纳入32项研究1865例CUP患者,以骨转移为主组最大(n=622)。
  • [18F]FDG PET/CT汇总原发肿瘤检出率:脑转移为主组0.74,肝转移为主组0.54,骨转移为主组0.49。
  • 其他部位检出率:肺0.46、腹膜0.38、淋巴结0.37、软组织0.35。

核心结论

  • 该个体患者数据Meta分析提示,[18F]FDG PET/CT识别CUP原发肿瘤的能力取决于转移部位分布。
  • 作者认为这一发现强调需要对不同患者人群采取更个体化的诊断方法。
  • 作者提出应研究新型PET示踪剂或全身(PET/)MRI等替代诊断工具。

研究设计与样本

  • 系统综述与个体患者数据(IPD)Meta分析,检索2005年1月至2024年2月的文献。
  • 纳入描述[18F]FDG PET/CT检测CUP原发肿瘤诊断效能的研究,共32项研究1865例患者。
  • 个体患者数据来自原文或向通讯作者索取,按主要转移部位分组。
  • 比较不同主要转移部位之间[18F]FDG PET/CT检测潜在原发肿瘤的诊断效能。

主要发现

  • 最大亚组为主要骨转移患者(n=622),其次为肝转移(n=369)、淋巴结转移(n=358)、脑转移(n=316)、腹膜转移(n=70)、肺转移(n=67)、软组织转移(n=23),其他/未定义转移为小样本组(n=40)。
  • [18F]FDG PET/CT识别原发肿瘤的汇总检出率:脑转移为主组0.74、肝转移为主组0.54、骨转移为主组0.49、肺转移为主组0.46、腹膜转移为主组0.38、淋巴结转移为主组0.37、软组织转移为主组0.35。

关键数值与推荐

  • [18F]FDG PET/CT识别原发肿瘤汇总检出率在脑转移为主组为0.74。
  • 肝转移为主组汇总检出率为0.54,骨转移为主组为0.49。
  • 肺转移为主组为0.46,腹膜转移为主组为0.38。
  • 淋巴结转移为主组为0.37,软组织转移为主组为0.35。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In this systematic review and individual patient data (IPD) meta-analysis, we analysed the diagnostic performance of [18F]FDG PET/CT in detecting primary tumours in patients with CUP and evaluated whether the location of the predominant metastatic site influences the diagnostic performance. METHODS: A systematic literature search from January 2005 to February 2024 was performed to identify articles describing the diagnostic performance of [18F]FDG PET/CT for primary tumour detection in CUP. Individual patient data retrieved from original articles or obtained from corresponding authors were grouped by the predominant metastatic site. The diagnostic performance of [18F]FDG PET/CT in detecting the underlying primary tumour was compared between predominant metastatic sites. RESULTS: A total of 1865 patients from 32 studies were included. The largest subgroup included patients with predominant bone metastases (n = 622), followed by liver (n = 369), lymph node (n = 358), brain (n = 316), peritoneal (n = 70), lung (n = 67), and soft tissue (n = 23) metastases, leaving a small group of other/undefined metastases (n = 40). [18F]FDG PET/CT resulted in pooled detection rates to identify the primary tumour of 0.74 (for patients with predominant brain metastases), 0.54 (liver-predominant), 0.49 (bone-predominant), 0.46 (lung-predominant), 0.38 (peritoneal-predominant), 0.37 (lymph node-predominant), and 0.35 (soft-tissue-predominant). CONCLUSION: This individual patient data meta-analysis suggests that the ability of [18F]FDG PET/CT to identify the primary tumour in CUP depends on the distribution of metastatic sites. This finding emphasises the need for more tailored diagnostic approaches in different patient populations. In addition, alternative diagnostic tools, such as new PET tracers or whole-body (PET/)MRI, should be investigated.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Willemse JRJ, Lambregts DMJ, Balduzzi S, et al. Identifying the primary tumour in patients with cancer of unknown primary (CUP) using [18F]FDG PET/CT: a systematic review and individual patient data meta-analysis. Eur J Nucl Med Mol Imaging. 2024. PMID: 39141069. doi:10.1007/s00259-024-06860-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。